Biophysical screening for the discovery of small-molecule ligands.
暂无分享,去创建一个
[1] Jonathan Bard,et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.
[2] Stephen W. Fesik,et al. One-Dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules , 1997 .
[3] T. Willson,et al. Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.
[4] J F Brandts,et al. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. , 1989, Analytical biochemistry.
[5] R. Spencer,et al. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. , 1998, Biotechnology and bioengineering.
[6] Harren Jhoti,et al. High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.
[7] T. Blundell,et al. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.
[8] J. Broach,et al. High-throughput screening for drug discovery. , 1996, Nature.
[9] Maxwell D Cummings,et al. Universal Screening Methods and Applications of ThermoFluor® , 2006, Journal of biomolecular screening.
[10] C. Schalk-Hihi,et al. Protein thermal shifts to identify low molecular weight fragments. , 2011, Methods in enzymology.
[11] W Bruce Turnbull,et al. On the value of c: can low affinity systems be studied by isothermal titration calorimetry? , 2003, Journal of the American Chemical Society.
[12] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[13] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[14] Harald Schwalbe,et al. Perspectives on NMR in drug discovery: a technique comes of age , 2008, Nature Reviews Drug Discovery.
[15] Jean M. Severin,et al. Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .
[16] S. Lampel,et al. The druggable genome: an update. , 2005, Drug discovery today.
[17] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[18] Stephen V Frye,et al. The art of the chemical probe. , 2010, Nature chemical biology.
[19] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[20] Julien Michel,et al. Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.
[21] Bernd Meyer,et al. Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.
[22] G. Fogliatto,et al. WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.
[23] Maria Paola Costi,et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. , 2008, Journal of medicinal chemistry.
[24] Tomas Lundqvist. The devil is still in the details--driving early drug discovery forward with biophysical experimental methods. , 2005, Current opinion in drug discovery & development.
[25] Chris Abell,et al. Inhibition of Mycobacterium tuberculosis Pantothenate Synthetase by Analogues of the Reaction Intermediate , 2008, Chembiochem : a European journal of chemical biology.
[26] Daniel A Erlanson,et al. Introduction to fragment-based drug discovery. , 2012, Topics in current chemistry.
[27] Craig M. Crews,et al. Targeting the undruggable proteome: the small molecules of my dreams. , 2010, Chemistry & biology.
[28] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[29] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[30] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[31] Stuart L Schreiber,et al. Small molecules: the missing link in the central dogma , 2005, Nature chemical biology.
[32] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[33] Hans-Joachim Böhm,et al. A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.
[34] George T Detitta,et al. Thermofluor-based high-throughput stability optimization of proteins for structural studies. , 2006, Analytical biochemistry.
[35] K. Strebhardt,et al. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. , 2008, Analytical biochemistry.
[36] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[37] P. Cole,et al. Chemical probes for histone-modifying enzymes. , 2008, Nature chemical biology.
[38] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[39] Chris Abell,et al. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. , 2009, Angewandte Chemie.
[40] Jeffrey W. Peng,et al. Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.
[41] Glyn Williams,et al. Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.
[42] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[43] Xinyi Huang,et al. Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. , 2003, Journal of biomolecular screening.
[44] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[45] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[46] S. Knapp,et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.
[47] Chris Abell,et al. Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.
[48] Brian K Shoichet,et al. Interpreting steep dose-response curves in early inhibitor discovery. , 2006, Journal of medicinal chemistry.